Team Introductions: Memorial Sloan Kettering “Yankees” vs Dana-Farber “Red Sox”

News
Video

Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

Russ Conroy
May 9th 2025
Article

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

Tim Cortese
April 30th 2025
Article

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL

Roman Fabbricatore
April 21st 2025
Article

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Roman Fabbricatore
April 9th 2025
Article

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.